Skip to main content

Branded

  • Report: Mylan looks to block Ranbaxy from making generic Lipitor

    NEW YORK — Generic drug maker Mylan is suing the Food and Drug Administration in an effort to prevent Gurgaon, India-based competitor Ranbaxy Labs from launching its generic version of Pfizer’s cholesterol medication Lipitor, according to published reports.

  • Lilly issues warning over alcohol prep pads associated with Forteo

    INDIANAPOLIS — Drug maker Eli Lilly is warning patients to avoid using alcohol prep pads that come with one of its osteoporosis drugs due to the risk of bacterial infections.

  • Journal notes heart-related risks posed by Avandia

    LONDON — With respect to the Type 2 diabetes drug Avandia, British drug maker GlaxoSmithKline has another medical study to worry about.

  • Report: Pfizer recalls Embeda

    NEW YORK — Pfizer is recalling a painkiller drug it acquired when it bought King Pharmaceuticals due to problems with a chemical used to deter drug abuse, according to a published report.

    Reuters reported that Pfizer had recalled supplies of Embeda (morphine sulfate and naltrexone hydrochloride) because the chemical that prevents the drug from being ground up or dissolved by drug abusers — naltrexone — had deteriorated in samples of the drug that Pfizer had tested.

    The drug has sales of less than $70 million per year, according to Reuters.

  • NACDS responds to report on integrity of pharmaceutical supply chain

    ALEXANDRIA, Va. — Commenting on a counterfeit pharmaceutical inter-agency working group report, the National Association of Chain Drug Stores stressed that it shares the goal of improving the public awareness of the risks posed from counterfeit drugs and unlawful online drug sellers, but expressed concern over the report's proposal to mandate a "track-and-trace" system in the United States, given the high cost it could pose for pharmacies.

  • Gilead, Roche sue Natco Pharma over generic Tamiflu

    NEW YORK — Drug makers Gilead Sciences and Roche are suing Indian drug maker Natco Pharma concerning a generic version of an influenza treatment, according to published reports.

    Bloomberg reported that Gilead and Roche were accusing Natco of patent infringement due to its efforts to gain approval from the Food and Drug Administration for a generic version of Tamiflu (oseltamivir phosphate). Natco became the first company to file for approval of a generic version in February.

  • Late-stage trial to commence for AstraZeneca's opioid-induced constipation treatment

    WILMINGTON, Del. — Anglo-Swedish drug maker AstraZeneca has enrolled the first patient in a late-stage clinical trial for a drug to treat constipation related to use of opioid painkillers, the company said.

  • WAG VP talks to Chicago Tribune about changing role of pharmacist

    CHICAGO — New federal and state regulations are expanding the role of the pharmacist, noted Richard Ashworth, Walgreens VP pharmacy services, during a live “Health Chat” hosted by Chicago Tribune reporter Bruce Japsen on Thursday afternoon. And that’s of benefit to patients at large, especially as “community pharmacy is located in the local communities and [is] a natural extension of the healthcare system,” Ashworth wrote.

X
This ad will auto-close in 10 seconds